Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Excess Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Screened Cohort of Patients with Gaucher Disease (GD)

Majdolen Joleen Istaiti, Katie Thoren, Shoshana Revel-Vilk, Ari Zimran, Ola Landgren

Blood (2024) 144 (Supplement 1): 3294.

https://doi.org/10.1182/blood-2024-194457

Published: 2024

Journal Articles

Enhanced Detection of M-Protein in Non-Secretory and Oligo-Secretory Multiple Myeloma Using MALDI-TOF Mass Spectrometry

Gil Hevroni, Katie Thoren, Dan C. Qu, Elizabeth Lyubchenko, Elena Bosack, James E. Hoffman, Ola Landgren, Benjamin Diamond, Dickran Kazandjian, David G. Coffey

Blood (2024) 144 (Supplement 1): 6847.

https://doi.org/10.1182/blood-2024-205107

Published: 2024

Journal Articles

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Blood (2024) 144 (Supplement 1): 7049.

https://doi.org/10.1182/blood-2024-193966

Published: 2024

Journal Articles

Next-Generation Monitoring: M-Insight® Clinical Application in Multiple Myeloma

Mariel Coradin, Ravleen Virdi, Katie Thoren, Luciano Di Stefano, Vincent Bonifay, Caroline Rougé Dubroc, Fionn McLoughlin, Ola Landgren

Blood (2024) 144 (Supplement 1): 6967.

https://doi.org/10.1182/blood-2024-204061

Published: 2024

Journal Articles

Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,589 Service Members Deployed to Either Iraq, Germany, or Not-Deployed Ex-US with or without Reported Burn Pit and Toxic Smoke Exposure

Dickran Kazandjian, Christin DeStefano, Alexander Dew, Elizabeth Hill, Katie Thoren, Ola Landgren

Blood (2024) 144 (Supplement 1): 4669.

https://doi.org/10.1182/blood-2024-202196

Published: 2024

Journal Articles

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Blood (2023) 142 (Supplement 1): 6740.

https://doi.org/10.1182/blood-2023-180939

Published: 2023

Journal Articles

Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,068 Service Members Deployed to Either Europe or Iraq, with or without Reported Burn Pit and Toxic Smoke Exposure

Dickran Kazandjian, Christin DeStefano, Alexander Dew, Elizabeth Hill, Katie Thoren, Ola Landgren

Blood (2023) 142 (Supplement 1): 4770.

https://doi.org/10.1182/blood-2023-182169

Published: 2023

Journal Articles

Advances in Mass Spectrometry for Myeloma Minimal Residual Disease

Katie Thoren

Blood (2020) 136 (Supplement 1): SCI1.

https://doi.org/10.1182/blood-2020-133038

Published: 2020

Journal Articles

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study

Ola Landgren, MD PhD, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Hani Hassoun, MD, Carlyn Tan, MD, Urvi A Shah, MD, Sydney X. Lu, MD PhD, Benjamin Diamond, MD, Meghan Salcedo, RN, Kelly Werner, RN, Jenna Rispoli, RN, Julia Caple, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Isabel Concepcion, NP, Ciardello Amanda, MS, Aisara Chansakul, BS, Julia Schlossman, BA, Elizabet Tavitian, BS, Tala Shekarkhand, BS, Angela Harrison, MS, Casey Piacentini, BS, Even H Rustad, MD PhD, Venkata Yellapantula, PhD, Francesco Maura, MD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan Shah, MD, Oscar B Lahoud, MD, Katie Thoren, Kazunori Murata, PhD, Lakshmi Ramanathan, PhD, Maria E. Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Andriy Derkach, PhD, Sergio A. Giralt, MD, Neha Korde, MD

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-142466

Published: 2020

Journal Articles

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Benjamin Diamond, MD, Neha Korde, MD, Alexander M. Lesokhin, MD, Eric L Smith, MDPhD, Urvi A Shah, MD, Sham Mailankody, MBBS, Malin Hultcrantz, MD PhD, Hani Hassoun, MD, Sydney X. Lu, MD PhD, Carlyn Tan, MD, Donna Massey, MSN, RN, Meghan Salcedo, BSN, RN, Victoria Diab, RN, Kelly Werner, RN, Jenna Rispoli, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Julia Schlossman, BA, Aisara Chansakul, BS, Angela Harrison, MS, Amanda Kathryn Ciardiello, Elizabet Tavitian, BS, Tala Shekarkhand, BS, Casey Piacentini, BS, Even H Rustad, MD PhD, Venkata D Yellapantula, Francesco Maura, MD, Tim J Peterson, PharmD, Andriy Derkach, PhD, Sean Devlin, PhD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan L. Shah, MDMS, Oscar B Lahoud, MD, Katie Thoren, Kazunori Murata, Lakshmi Ramanathan, PhD, Maria E. Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Sergio A. Giralt, MD, Ola Landgren, MD PhD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-140152

Published: 2020

Journal Articles

Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients with Multiple Myeloma

Marion Eveillard, Even H Rustad, MD, Mikhail Roshal, MD PhD, Yanming Zhang, MD, Amanda Kathryn Ciardiello, Neha Korde, MD, Malin Hultcrantz, MD PhD, Hani Hassoun, MD, Eric L Smith, MD PhD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Ola Landgren, MD PhD, Katie Thoren, PhD

Blood (2019) 134 (Supplement_1): 3060.

https://doi.org/10.1182/blood-2019-123838

Published: 2019

Journal Articles

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

Blood (2019) 134 (Supplement_1): 862.

https://doi.org/10.1182/blood-2019-126378

Published: 2019

Journal Articles

MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy

Marion Eveillard, Malin Hultcrantz, MD PhD, Alexander M. Lesokhin, MD, Sham Mailankody, MBBS, Eric L Smith, MD PhD, Hani Hassoun, MD, Urvi A Shah, MD, Sydney X Lu, MD PhD, Neha Korde, MD, Ola Landgren, MD PhD, Katie Thoren, PhD

Blood (2019) 134 (Supplement_1): 4377.

https://doi.org/10.1182/blood-2019-128938

Published: 2019

Journal Articles

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Ola Landgren, MD PhD, Donna Mastey, RN, Alexander M. Lesokhin, MD, Eric L Smith, MD PhD, Urvi A Shah, MD, Sham Mailankody, MBBS, Malin Hultcrantz, MD PhD, Hani Hassoun, MD, Sydney X Lu, MD PhD, Meghan Salcedo, RN, Victoria Diab, RN, Kelly Werner, RN, Jenna Rispoli, RN, Allison Sams, NP, Dennis Verducci, NP, Katie Jones, NP, Julia Schlossman, BA, Aisara Chansakul, BS, Angela Harrison, MS, Amanda Ciardiello, BS, Elizabeth Tavitian, BS, Tala Shekarkhand, BS, Even Rustad, MD, Venkata Yellapantula, PhD, Francesco Maura, MD, Tim J Peterson, PharmD, Sean M. Devlin, PhD, Heather J Landau, MD, Michael Scordo, MD, David J. Chung, MD PhD, Gunjan Shah, MD, Oscar B Lahoud, MD, Katie Thoren, PhD, Kazunori Murata, PhD, Lakshmi Ramanathan, PhD, Maria E Arcila, MD, Caleb Ho, MD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD, Sergio Giralt, MD, Neha Korde, MD

Blood (2019) 134 (Supplement_1): 3127.

https://doi.org/10.1182/blood-2019-125842

Published: 2019

Journal Articles

Bone Marrow-Based and Longitudinal Blood-Based MRD Tracking in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd): A Correlative and Clinical Phase II Study

Blood (2018) 132 (Supplement 1): 3281.

https://doi.org/10.1182/blood-2018-99-114311

Published: 2018

NARROW

Excess Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Screened Cohort of Patients with Gaucher Disease (GD)

Enhanced Detection of M-Protein in Non-Secretory and Oligo-Secretory Multiple Myeloma Using MALDI-TOF Mass Spectrometry

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Next-Generation Monitoring: M-Insight® Clinical Application in Multiple Myeloma

Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,589 Service Members Deployed to Either Iraq, Germany, or Not-Deployed Ex-US with or without Reported Burn Pit and Toxic Smoke Exposure

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,068 Service Members Deployed to Either Europe or Iraq, with or without Reported Burn Pit and Toxic Smoke Exposure

Advances in Mass Spectrometry for Myeloma Minimal Residual Disease

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients with Multiple Myeloma

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study

MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study

Bone Marrow-Based and Longitudinal Blood-Based MRD Tracking in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd): A Correlative and Clinical Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only